JP2023545520A - 甲状腺眼疾患を治療するための組成物及び方法 - Google Patents
甲状腺眼疾患を治療するための組成物及び方法 Download PDFInfo
- Publication number
- JP2023545520A JP2023545520A JP2023523077A JP2023523077A JP2023545520A JP 2023545520 A JP2023545520 A JP 2023545520A JP 2023523077 A JP2023523077 A JP 2023523077A JP 2023523077 A JP2023523077 A JP 2023523077A JP 2023545520 A JP2023545520 A JP 2023545520A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- subject
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025109815A JP2025143343A (ja) | 2020-10-14 | 2025-06-27 | 甲状腺眼疾患を治療するための組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091839P | 2020-10-14 | 2020-10-14 | |
| US63/091,839 | 2020-10-14 | ||
| US202163201978P | 2021-05-21 | 2021-05-21 | |
| US63/201,978 | 2021-05-21 | ||
| US202163260130P | 2021-08-10 | 2021-08-10 | |
| US63/260,130 | 2021-08-10 | ||
| US202163261742P | 2021-09-28 | 2021-09-28 | |
| US63/261,742 | 2021-09-28 | ||
| PCT/US2021/054907 WO2022081799A1 (en) | 2020-10-14 | 2021-10-14 | Compositions and methods for treatment of thyroid eye disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025109815A Division JP2025143343A (ja) | 2020-10-14 | 2025-06-27 | 甲状腺眼疾患を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545520A true JP2023545520A (ja) | 2023-10-30 |
| JP2023545520A5 JP2023545520A5 (cg-RX-API-DMAC7.html) | 2025-07-08 |
Family
ID=81208791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523077A Pending JP2023545520A (ja) | 2020-10-14 | 2021-10-14 | 甲状腺眼疾患を治療するための組成物及び方法 |
| JP2025109815A Pending JP2025143343A (ja) | 2020-10-14 | 2025-06-27 | 甲状腺眼疾患を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025109815A Pending JP2025143343A (ja) | 2020-10-14 | 2025-06-27 | 甲状腺眼疾患を治療するための組成物及び方法 |
Country Status (18)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3195512A1 (en) * | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| JP2024531151A (ja) * | 2021-08-10 | 2024-08-29 | ビリジアン セラピューティクス, インコーポレイテッド | 甲状腺眼疾患の処置のための組成物、用量および方法 |
| CN119823995A (zh) * | 2022-12-06 | 2025-04-15 | 中南大学湘雅三医院 | 一种靶向cd34阳性眼眶成纤维细胞的核酸适配体及其应用 |
| CN122122186A (zh) | 2023-09-06 | 2026-05-29 | 维里迪安治疗公司 | 抗igf-1r抗体的药物组合物 |
| AU2024408268A1 (en) * | 2023-12-17 | 2026-07-09 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
| WO2025151496A1 (en) * | 2024-01-09 | 2025-07-17 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| WO2025151492A1 (en) * | 2024-01-09 | 2025-07-17 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| WO2026044000A1 (en) * | 2024-08-20 | 2026-02-26 | Ethyreal Bio, Inc. | Multispecific antibodies and methods of use thereof |
| WO2026095974A1 (en) | 2024-10-30 | 2026-05-07 | Horizon Therapeutics Ireland Dac | Methods of treating thyroid eye disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513278A (ja) * | 2006-12-13 | 2010-04-30 | シェーリング コーポレイション | Igf1rインヒビターを用いた癌の処置方法 |
| WO2019173352A1 (en) * | 2018-03-05 | 2019-09-12 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| JP2020518674A (ja) * | 2017-05-05 | 2020-06-25 | フュージョン・ファーマシューティカルズ・インコーポレイテッド | Igf−1rモノクローナル抗体及びその使用 |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4949778A (en) | 1987-12-16 | 1990-08-21 | Kawasaki Steel Corporation | Immersion nozzle for continuous casting |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| ES2210306T3 (es) | 1994-07-20 | 2004-07-01 | The General Hospital Corporation | Sistemas de trampa para interacciones, para detectar interacciones de proteinas. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| ES2402878T3 (es) | 1999-05-05 | 2013-05-10 | Phylogica Limited | Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos |
| DE60045243D1 (de) | 1999-05-26 | 2010-12-30 | Next Biomed Technologies Nbt Oy | VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US7998681B2 (en) | 2000-10-06 | 2011-08-16 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders |
| US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
| NZ527302A (en) | 2001-01-05 | 2006-10-27 | Abgenix Inc | Antibodies to insulin-like growth factor I receptor |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| MXPA04011624A (es) | 2002-05-24 | 2005-03-07 | Schering Corp | Anticuerpo neutralizante humano anti-igfr. |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| WO2004031733A2 (en) | 2002-10-02 | 2004-04-15 | Catalyst Biosciences | Methods of generating and screenign for porteases with altered specificity |
| PT1587907E (pt) | 2003-01-07 | 2011-04-08 | Dyax Corp | Biblioteca de domínios de kunitz |
| KR20050109489A (ko) | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 i 수용체 항체의 용도 |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| CN101014365B (zh) * | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2281841A3 (en) | 2004-12-03 | 2013-10-23 | Merck Sharp & Dohme Corp. | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| BRPI0611800A2 (pt) | 2005-06-15 | 2008-12-09 | Schering Corp | formulaÇço estÁvel de anticorpo |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007045465A1 (en) * | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| WO2007062037A2 (en) | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| US8603465B1 (en) | 2006-08-07 | 2013-12-10 | Merck Sharp & Dohme, Corp. | Methods for treatment of polyposis |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US20100143340A1 (en) | 2006-12-13 | 2010-06-10 | Schering Corporation | Methods and compositions for treating cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008079849A2 (en) * | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| SI2185589T1 (sl) | 2007-06-01 | 2016-04-29 | University Of Maryland Baltimore | Vezavna sredstva za Fc receptor konstantne regije imunoglobulina |
| US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| JP2011525180A (ja) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| RU2011116319A (ru) | 2008-09-26 | 2012-11-10 | Шеринг Корпорейшн (US) | Производство высокого титра антител |
| US8137933B2 (en) | 2008-11-12 | 2012-03-20 | Schering Corporation | Mammalian expression vector pUHAB |
| EP2419136A4 (en) * | 2009-04-16 | 2013-01-02 | Merck Sharp & Dohme | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| WO2010127284A2 (en) | 2009-05-01 | 2010-11-04 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| MX2012002651A (es) | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| WO2011057064A1 (en) | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
| US9045536B2 (en) * | 2009-12-23 | 2015-06-02 | Merck Sharp & Dohme Corp. | Cell line 3M |
| WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| JP5985481B2 (ja) | 2010-09-01 | 2016-09-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗イディオタイプ抗体の迅速な産生 |
| UY33707A (es) | 2010-11-04 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20120201746A1 (en) | 2010-12-22 | 2012-08-09 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 一価抗原結合タンパク質 |
| AU2012255251B2 (en) | 2011-05-18 | 2017-06-15 | University Of Florida Research Foundation, Inc. | Macrocyclic therapeutic agents and methods of treatment |
| AU2012255920A1 (en) * | 2011-05-18 | 2013-11-07 | Merck Sharp & Dohme Corp. | Therapeutic anti-IGF1R combinations |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| TW201333039A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 雙可變域免疫球蛋白及其用途 |
| CA2864432A1 (en) | 2012-02-15 | 2013-08-22 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| EP2852685A1 (en) * | 2012-03-30 | 2015-04-01 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
| WO2013169611A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
| EP2863947B1 (en) | 2012-06-21 | 2018-03-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| NZ711373A (en) | 2013-03-13 | 2020-07-31 | Bioasis Technologies Inc | Fragments of p97 and uses thereof |
| TW201920285A (zh) | 2013-04-29 | 2019-06-01 | 瑞士商赫孚孟拉羅股份公司 | 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途 |
| CA2904806C (en) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US20210138076A2 (en) | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| MA39909B1 (fr) | 2014-04-25 | 2019-05-31 | Pf Medicament | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer |
| WO2016004389A2 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Monovalent binding proteins |
| WO2016064716A1 (en) | 2014-10-20 | 2016-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination therapy of tshr antagonist and igfr inhibitor |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3493845A4 (en) * | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| JP7186400B2 (ja) | 2016-08-30 | 2022-12-09 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | ゲノム的に再コードした生物におけるセレノ-生物製剤の製造 |
| EP3516068B1 (en) | 2016-09-19 | 2025-04-23 | University of Southern California | Non-radioactive cytotoxicity assays |
| HRP20250482T1 (hr) * | 2016-12-21 | 2025-06-20 | Cephalon Llc | Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe |
| CN106546800B (zh) | 2017-01-25 | 2019-06-18 | 北京鸿智电通科技有限公司 | 一种应用于快充电源的充/放电电流检测电路 |
| US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| CA3056573A1 (en) | 2017-05-30 | 2018-12-06 | Teijin Pharma Limited | Anti-igf-i receptor antibody |
| SG11202002489YA (en) | 2017-10-06 | 2020-04-29 | Prothena Biosciences Ltd | Anti-transthyretin antibodies |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
| US20210284741A1 (en) | 2018-01-24 | 2021-09-16 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| US11208489B2 (en) * | 2018-01-24 | 2021-12-28 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| WO2019183523A1 (en) | 2018-03-23 | 2019-09-26 | Genentech, Inc. | Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl) |
| EP4036014B1 (en) * | 2018-03-28 | 2024-05-01 | Airbus Operations GmbH | Fuselage assembly for an aircraft |
| WO2020006486A1 (en) | 2018-06-29 | 2020-01-02 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
| JP6958530B2 (ja) * | 2018-10-10 | 2021-11-02 | セイコーエプソン株式会社 | 光学モジュールおよび頭部装着型表示装置 |
| KR20210099073A (ko) * | 2018-12-03 | 2021-08-11 | 퓨전 파마슈티칼즈 인크. | 방사성면역접합체와 체크포인트 억제제의 조합 요법 |
| SI3898668T1 (sl) * | 2018-12-19 | 2024-02-29 | Humabs Biomed Sa | Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe |
| CN111744013B (zh) | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
| JP2022545835A (ja) * | 2019-08-28 | 2022-10-31 | ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー | 甲状腺眼症の治療方法 |
| CN113402602B (zh) | 2020-03-17 | 2022-09-23 | 上海祥耀生物科技有限责任公司 | 一种新型冠状病毒SARS-CoV-2中和性抗体及应用 |
| WO2021243014A1 (en) | 2020-05-28 | 2021-12-02 | Horizon Therapeutics Ireland Dac | Methods for the treatment of idiopathic orbital inflammation and related conditions |
| CA3195512A1 (en) | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| TW202246339A (zh) | 2021-03-03 | 2022-12-01 | 愛爾蘭商赫萊森治療愛爾蘭公司 | 治療甲狀腺眼疾的方法 |
| EP4123454A1 (en) | 2021-07-21 | 2023-01-25 | Abb Schweiz Ag | Validating component specifications for industrial automation systems |
| JP2024531151A (ja) | 2021-08-10 | 2024-08-29 | ビリジアン セラピューティクス, インコーポレイテッド | 甲状腺眼疾患の処置のための組成物、用量および方法 |
| JP2024532482A (ja) | 2021-09-01 | 2024-09-05 | バイオセプター (オースト) プロプライエタリー・リミテッド | 免疫活性を刺激するための方法および組成物 |
| MX2024007968A (es) * | 2021-12-23 | 2024-07-29 | Viridian Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. |
| CA3242661A1 (en) | 2022-01-07 | 2023-07-13 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| CN118679187A (zh) | 2022-01-07 | 2024-09-20 | 维里迪安治疗公司 | 用于治疗甲状腺眼疾病的组合物和方法 |
| JP2025503637A (ja) | 2022-01-09 | 2025-02-04 | クリヤ セラピューティクス, インコーポレイテッド | 治療用抗igf-1r抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法 |
| CN122003247A (zh) | 2023-07-07 | 2026-05-08 | 维里迪安治疗公司 | 治疗活动性和慢性甲状腺眼病的方法 |
| CN122122186A (zh) | 2023-09-06 | 2026-05-29 | 维里迪安治疗公司 | 抗igf-1r抗体的药物组合物 |
-
2021
- 2021-10-14 CA CA3195512A patent/CA3195512A1/en active Pending
- 2021-10-14 JP JP2023523077A patent/JP2023545520A/ja active Pending
- 2021-10-14 US US17/450,872 patent/US20220235137A1/en not_active Abandoned
- 2021-10-14 WO PCT/US2021/054914 patent/WO2022081804A1/en not_active Ceased
- 2021-10-14 MX MX2023004280A patent/MX2023004280A/es unknown
- 2021-10-14 US US17/501,362 patent/US20220267450A1/en not_active Abandoned
- 2021-10-14 CR CR20230204A patent/CR20230204A/es unknown
- 2021-10-14 CN CN202411943834.6A patent/CN119792512A/zh active Pending
- 2021-10-14 IL IL302068A patent/IL302068A/en unknown
- 2021-10-14 US US17/501,430 patent/US20220267451A1/en not_active Abandoned
- 2021-10-14 CA CA3195590A patent/CA3195590A1/en active Pending
- 2021-10-14 AU AU2021360889A patent/AU2021360889A1/en active Pending
- 2021-10-14 KR KR1020237016151A patent/KR20230124550A/ko active Pending
- 2021-10-14 CN CN202610216995.8A patent/CN122127457A/zh active Pending
- 2021-10-14 TW TW110138163A patent/TW202228775A/zh unknown
- 2021-10-14 CN CN202411945416.0A patent/CN119792513A/zh active Pending
- 2021-10-14 CN CN202180084040.7A patent/CN116583273B/zh active Active
- 2021-10-14 PE PE2023001413A patent/PE20231202A1/es unknown
- 2021-10-14 WO PCT/US2021/054907 patent/WO2022081799A1/en not_active Ceased
- 2021-10-14 EP EP21881056.2A patent/EP4228616A4/en active Pending
- 2021-10-14 TW TW110138121A patent/TW202229350A/zh unknown
- 2021-10-14 CN CN202610217033.4A patent/CN122031679A/zh active Pending
-
2022
- 2022-04-20 US US17/724,639 patent/US20220275096A1/en not_active Abandoned
- 2022-08-29 US US17/822,978 patent/US11548951B1/en active Active
-
2023
- 2023-01-05 US US18/150,514 patent/US12404335B2/en active Active
- 2023-04-12 CL CL2023001052A patent/CL2023001052A1/es unknown
- 2023-04-13 JO JOJO/P/2023/0075A patent/JOP20230075A1/ar unknown
- 2023-04-13 DO DO2023000073A patent/DOP2023000073A/es unknown
- 2023-05-10 CO CONC2023/0005996A patent/CO2023005996A2/es unknown
- 2023-05-11 EC ECSENADI202334914A patent/ECSP23034914A/es unknown
- 2023-08-03 US US18/364,620 patent/US20240043546A1/en active Pending
-
2024
- 2024-11-08 US US18/942,051 patent/US12595309B2/en active Active
-
2025
- 2025-06-18 US US19/242,715 patent/US20250313639A1/en active Pending
- 2025-06-18 US US19/242,725 patent/US12600788B2/en active Active
- 2025-06-27 JP JP2025109815A patent/JP2025143343A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513278A (ja) * | 2006-12-13 | 2010-04-30 | シェーリング コーポレイション | Igf1rインヒビターを用いた癌の処置方法 |
| JP2020518674A (ja) * | 2017-05-05 | 2020-06-25 | フュージョン・ファーマシューティカルズ・インコーポレイテッド | Igf−1rモノクローナル抗体及びその使用 |
| WO2019173352A1 (en) * | 2018-03-05 | 2019-09-12 | Hznp Limited | Methods for the treatment of thyroid eye disease |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12595309B2 (en) | Compositions and methods for treatment of thyroid eye disease | |
| US12404337B2 (en) | Compositions, doses, and methods for treatment of thyroid eye disease | |
| AU2022420605A1 (en) | Compositions and methods for treatment of thyroid eye disease | |
| JP2025503339A (ja) | 甲状腺眼疾患を治療するための組成物及び方法 | |
| JP2025503614A (ja) | 甲状腺眼疾患を治療するための組成物及び方法 | |
| CN118059229A (zh) | 用于治疗甲状腺眼病的组合物和方法 | |
| HK40117748A (en) | Compositions and methods for treatment of thyroid eye disease | |
| HK40099096B (en) | Compositions and methods for treatment of thyroid eye disease | |
| HK40099096A (en) | Compositions and methods for treatment of thyroid eye disease | |
| HK40097533A (en) | Compositions and methods for treatment of thyroid eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240826 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241011 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241011 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20241120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241120 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250627 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20250627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250729 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20251028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260602 |